We are highly indebted to Dr. Finn Bo Petersen (Salt Lake City, UT) and Dr. C. Dean Buckner (Seattle, WA) for their advice and critical review of this article.
Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation†
Prospective clinical and socioeconomic evaluation
Version of Record online: 14 AUG 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 3, pages 602–611, 1 February 2013
How to Cite
Blaise, D., Tabrizi, R., Boher, J.-M., Le Corroller-Soriano, A.-G., Bay, J.-O., Fegueux, N., Boiron, J.-M., Fürst, S., Castagna, L., Chabannon, C., Boyer-Chammard, A., Milpied, N., Labussière-Wallet, H., Faucher, C., Bardou, V.-J., Mohty, M. and Michallet, M. (2013), Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation. Cancer, 119: 602–611. doi: 10.1002/cncr.27786
The first author designed the study, performed the research, analyzed data, interpreted results, and drafted the article; the third author analyzed data and drafted the article; the fourth author analyzed data, interpreted results, and drafted the article; the fifth and seventh authors and the last four authors designed the study, performed the research, and critically reviewed and revised the article; the second and sixth authors and the eighth through 13th authors performed the research and critically reviewed and revised the article; and all authors approved the final version.
- Issue online: 22 JAN 2013
- Version of Record online: 14 AUG 2012
- Manuscript Accepted: 18 JUL 2012
- Manuscript Revised: 10 JUL 2012
- Manuscript Received: 2 MAR 2012
- 9Phase II selection designs. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. Seattle, WA: Marcel Dekker; 2001: 119–127.
- 17Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104: 865–872., , , et al.
- 20Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011; 17: 1490–1496., , , et al.
- 29The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2010; 16: 509–514., , , et al.